entertainment -WSS

entertainment

author：Wikipedia 2025-10-03 01:05:01 - browse：6739

In the center, three researchers examine a DNA helix. Two people stand in the front, one puts an apple into a capsule containing vegetables, the other holds a check list while standing next to a pile of medicines. On the right side, a scientist injects into mitochondria while another takes notes. A person behind the duo looks at a projection of a brain. On the left side, a client looks at a heart projection from a device held by a robot — biotech coverage from STAT — Adobe

When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, the maker of the weight loss drug Wegovy, is tops, according to a new analysis.

But if you want to invent lots of potential drugs that could eventually reach the market, you’d be far better off with Johnson & Johnson, Merck, or AstraZeneca.

The analysis, the 13th edition of the Pharmaceutical Innovation and Invention Index, was produced by the consultancy Idea Pharma and released Thursday at the STAT Breakthrough Summit in San Francisco.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： We're not in Australia anymore: Kansas cops jump into action to save kangaroo

WSS

Key House panel plots a new health care package

Xenotransplantation trials will require adjusting expectations, experts say

In early work, researchers turn to CRISPR to treat Alzheimer's

The thinking behind the controversial eating disorder chatbot Tessa

Listen: Wegovy in the brain & pivotal Alzheimer's data

Biden administration plans revamp of organ transplant system

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA approves RSV monoclonal antibody for infants, toddlers

Psychedelics group wrestles with new pharma identity

FDA approves RSV monoclonal antibody for infants, toddlers

How to save PrEP access — and even expand it

Sanders adds drug shortage policies to pandemic preparedness bill

Drug repurposing or repositioning? The language matters

Biden tests positive for Covid

focus

Mom launches Girl Scout troop for LGBTQ youth in Texas

At Orexo, a ‘turning point’ for everything but digital health

Sanofi seeks simpler, safer CRISPR sickle cell cure

Biogen nominates mother of director’s child to replace him on board

How Medicaid coverage policies for immigrants impact new moms

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

explore

hotspot

focus

Wikipedia